Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Sanofi top pharmaceutical products 2017-2018

Sanofi's selected top pharmaceutical products based on revenue in 2017 and 2018 (in million euros)

by Matej Mikulic, last edited Aug 9, 2019
Sanofi top pharmaceutical products 2017-2018 Lantus was Sanofi’s best-selling pharmaceutical product in 2018 according to the company’s latest annual financial report. The long-acting insulin (glargine), used to treat diabetes type I and II, generated nearly 3.6 billion U.S. dollars worldwide. Lantus has been among the company’s top products for many years but has shown significant decrease in revenue since the patent expired during 2015. In 2016, Sanofi introduced a much more potent formulation of insulin glargine under the brand name Toujeo.
Diabetes treatment

Diabetes is one of the most prevalent chronic diseases worldwide. Accordingly, antidiabetics form one of the three largest therapy classes within the global pharmaceutical market. Diabetes means that the human body is not able to produce its own insulin or use its insulin effectively. While persons with type 1 diabetes always need insulin for treatment, diabetes type 2 patients do not necessarily need it. A key medicine for persons with type 2 diabetes is metformin which helps to control blood sugar and to use insulin effectively. Change in lifestyle, a balanced diet, and physical activity might also be important parts of diabetes treatment.

The diabetes market

As mentioned, the diabetes segment is one of the largest single therapy classes within the pharmaceutical market, generating over 72 billion U.S. dollars in 2017. With projected increasing numbers of people affected worldwide until 2045, the diabetes market is also expected to grow. Currently, French company Sanofi is the world’s second largest antidiabetics manufacturing company based on revenue, only topped by Danish company Novo Nordisk. It is expected that Novo Nordisk will extend its market share in the diabetes sector up to 35 percent until 2024, thus maintaining the global leading position.
Show more

Sanofi's selected top pharmaceutical products based on revenue in 2017 and 2018 (in million euros)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Sanofi
Sanofi

All Information
in one Presentation

Sanofi

Everything On "Sanofi" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Sanofi"
  • Global positioning
  • Overview
  • Revenue distribution
  • Company shares
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.